Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06945406
PHASE1

A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it. The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 6 weeks for Part B and 7 weeks for Part C, all approximations, excluding a screening period.

Official title: A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

124

Start Date

2025-05-16

Completion Date

2026-12

Last Updated

2026-03-11

Healthy Volunteers

Yes

Interventions

DRUG

LY4057996 SC

Administered SC

DRUG

LY4057996 IV

Administered IV

DRUG

Placebo SC

Administered SC

DRUG

Placebo IV

Administered IV

DRUG

Degludec SC

Administered SC

DRUG

Lispro SC

Administered SC

DRUG

Degludec IV

Administered IV

DRUG

Pre-study basal insulin SC

Administered SC

Locations (1)

Profil Institut für Stoffwechselforschung

Neuss, Germany